hydromorphone extended release / Generic mfg. - LARVOL DELTA

A Comparative Study of Medication Adherence Between Hydromorphone Extended-Release Tablets and Oxycodone Extended-Release Tablets in Patients with Moderate to Severe Cancer Pain (ChiCTR) - P4 | N=296 | Not yet recruiting | Sponsor: Quanzhou First Hospital Affiliated to Fujian Medical University; Quanzhou First Hospital Affiliated to Fujian Medical University

New P4 trial • Oncology • Pain

Selective Uptake of Oral Extended-Release Hydromorphone After Formulary Listing in Cancer Care. (PubMed, J Pain Palliat Care Pharmacother) - No abstract available

Journal • Oncology

Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Qinghai Red Cross Hospital | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2026 ➔ Aug 2026

Enrollment open • Trial initiation date • Oncology • Pain

NCI-2018-01124: Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery (clinicaltrials.gov) - P3 | N=101 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Jul 2026 ➔ Jul 2027 | Trial primary completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Hepatology • Pain

A randomized, open label, controlled multicenter clinical study comparing the safety and efficacy of hydromorphone sustained-release tablets and hydrocodone sustained-release tablets in the treatment of elderly cancer pain patients in China (ChiCTR) - P=N/A | N=184 | Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

New trial • Oncology • Pain

Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Qinghai Red Cross Hospital

New P1 trial • Oncology • Pain

NCI-2018-01124: Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery (clinicaltrials.gov) - P3 | N=101 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatology • Pain

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: University of North Carolina, Chapel Hill | N=46 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Pain • Substance Abuse

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine (clinicaltrials.gov) - P4 | N=46 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Trial completion date: Jan 2027 ➔ Jan 2029 | Trial primary completion date: Jan 2027 ➔ Jan 2029

Trial completion date • Trial primary completion date • Pain • Substance Abuse

A multicenter, phase II clinical study on the successful titration of hydromorphone IPCA in patients with severe cancer pain and the conversion to hydromorphone sustained-release tablets for maintenance therapy (ChiCTR) - P2 | N=84 | Not yet recruiting | Sponsor: Fujian Cancer Hospital; Fujian Cancer Hospita

New P2 trial • Oncology • Pain

The Efficacy and Safety of Hydromorphone Hydrochloride Extended-release Tablets in patients with moderate to severe cancer pain:a multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled clinical trial. (ChiCTR) - P3 | N=240 | Completed | Sponsor: Henan Cancer Hospital; Yichang Humanwell Pharmaceutical ., LTD

New P3 trial • Oncology • Pain

Observational study of sustained-release hydromorphone tablets for refractory cancer pain in China (ChiCTR) - P=N/A | N=100 | Not yet recruiting | Sponsor: The second affiliated hospital of Zhejiang University school of medicine; The second affiliated hospital of Zhejiang University school of medicine

New trial • Oncology • Pain

Application of OROS® Hydromorphone in cancer pain patients with poor analgesic effect of oxycodone hydrochloride sustained-release tablets (ChiCTR) - P=N/A | N=136 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

New trial • Oncology • Pain

Comparison of Hydromorphone Extended Release Tablets after Titration with Morphine in the Treatment of Cancer Pain (ChiCTR) - P=N/A | N=60 | Not yet recruiting | Sponsor: Kunming Yan 'an Hospital; Kunming Yan 'an Hospital

New trial • Oncology • Pain

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine (clinicaltrials.gov) - P4 | N=46 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Initiation date: May 2025 ➔ Aug 2025

Trial initiation date • Pain • Substance Abuse

Hydromorphone PCA Titration Followed by Maintenance Using Extended-release Tablets for The Management of Severe Cancer Pain: A Randomized Controlled Trial (ChiCTR) - P4 | N=64 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital

New P4 trial • Oncology • Pain

Comparison of Hydromorphone Extended Release Tablets and Oxycodone in the Treatment of Chronic Pain (ChiCTR) - P4 | N=190 | Not yet recruiting | Sponsor: Shenzhen Nanshan People's Hospital; Shenzhen Nanshan People's Hospital

New P4 trial • Pain

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine (clinicaltrials.gov) - P4 | N=46 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Not yet recruiting ➔ Recruiting

Enrollment open • Pain • Substance Abuse

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine (clinicaltrials.gov) - P4 | N=46 | Not yet recruiting | Sponsor: University of North Carolina, Chapel Hill

New P4 trial • Pain • Substance Abuse

A CASE OF OPIOID WITHDRAWAL-INDUCED TAKOTSUBO CARDIOMYOPATHY (CHEST 2024) - "Review of outpatient records noted her usual hydromorphone ER 8 mg QD, hydromorphone IR 4 mg Q4H, and clonazepam were abruptly decreased to only hydromorphone 4 mg IR Q6H. Early detection and management of takotsubo prevents catastrophic complications like cardiogenic shock."

Clinical • Back Pain • Cardiomyopathy • Cardiovascular • CNS Disorders • Depression • Musculoskeletal Pain • Myocardial Infarction • Pain • Psychiatry • Respiratory Diseases • Ventricular Tachycardia

Comparison of the effects of OPRM1 A118G polymorphism using different opioids: A prospective study. (PubMed, J Pain Symptom Manage) - "Tapentadol and methadone may be more suitable than hydromorphone, oxycodone, and fentanyl for G-allele carriers due to their dual mechanism of action and low susceptibility to OPRM1 A118G polymorphism."

Journal • Oncology • Pain • OPRM1

Differences in the Analgesic Effect of Opioids on Pain in Cancer Patients With Spinal Metastases. (PubMed, Palliat Med Rep) - "A total of 274 patients were enrolled, who started a tapentadol extended-release tablet, methadone tablet, hydromorphone extended-release tablet, oxycodone extended-release tablet, or transdermal fentanyl patch for cancer pain due to spinal metastasis in Japan from January 1, 2013 to October 31, 2021. In patients without numbness, no significant differences were observed in decreases of the NRS scores on day seven among the five groups. Tapentadol and methadone may be more effective than hydromorphone, oxycodone, and fentanyl for cancer pain due to spinal metastasis with numbness."

Journal • Back Pain • Musculoskeletal Pain • Neuralgia • Oncology • Pain • Solid Tumor

NCI-2018-01124: Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery (clinicaltrials.gov) - P3 | N=96 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Aug 2024 ➔ Jul 2026 | Trial primary completion date: Aug 2023 ➔ Jul 2026

Surgery • Trial completion date • Trial primary completion date • Hepatology • Pain

Controlled-release hydromorphone and risk of infection in adults: a systematic review. (PubMed, Harm Reduct J) - "Very few studies have examined the risk of IE, HCV, and HIV infection after exposure to controlled-release hydromorphone. Very low-quality and scant evidence suggests uncertainty around the risks of blood-borne infections, such as HCV and IE to PWID using this medication."

Journal • Retrospective data • Review • Cardiovascular • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

NCI-2018-01124: Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery (clinicaltrials.gov) - P3 | N=96 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Aug 2023 ➔ Aug 2024 | Trial primary completion date: Aug 2022 ➔ Aug 2023

Surgery • Trial completion date • Trial primary completion date • Hepatology • Pain